埃拉米普雷提德:第一个针对巴斯综合征的心脏脂素导向线粒体治疗药物,已在加速批准下获得批准
Chenru Zhao1, Xuemei Zhuang1, Jianjun Gao2
1Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China.
Drug discoveries & therapeutics
|November 19, 2025
概括
埃拉米普雷提德是FDA批准的第一种治疗巴斯综合征 (BTHS) 的疗法,这是一种罕见的线粒体疾病. 虽然最初的试验没有显示出明显改善步行或疲劳,但长期使用证明了持续的益处.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 巴斯综合征 (BTHS) 是一种罕见的X相关线粒体疾病.
- 由tafazzin突变引起的,它损害了心血管蛋白重塑,导致线粒体功能障碍.
- 症状包括心肌病变,肌病变和中性质减退,代表了大量未满足的医疗需求.
研究的目的:
- 评估elamipretide的疗效和安全性,这是一种针对BTHS线粒体病因的新疗法.
- 评估elamipretide对BTHS患者临床结果和线粒体功能的影响.
主要方法:
- 进行了一项随机,双盲,安慰剂控制,交叉试验.
- 参与者接受了elamipretide或安慰剂,随后是开放式延长阶段.
- 主要终点包括6分钟步行测试和疲劳得分.
主要成果:
- 在最初的试验中,elamipretide在6分钟步行测试或疲劳得分中没有显著改善.
- 然而,在168周的开放性延长期内,观察到持续的临床益处.
- 最常见的不良事件是轻微的注射部位反应,表明了有利的安全性.
结论:
- 埃拉米普雷提德获得了FDA的加速批准,作为第一个直接针对BTHS线粒体功能障碍的治疗方法.
- 虽然最初的疗效终点没有达到,但长期数据表明持续的益处.
- 埃拉米普雷提德为BTHS提供了一个有前途的治疗选择,并为未来针对线粒体的治疗铺平了道路.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
316
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
316
01:16Therapeutic Drug Monitoring: Overview and Classification
279
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
279
01:26FDA Approved Drugs: Changes to Approved Drugs
235
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
235
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
419
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443